Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue (2011 - 2013)
Catalyst Pharmaceuticals' (CPRX) quarterly Non-Current Deffered Revenue came in at $19131.0 in Q4 2013, down 12.56% YoY from $21878.0 in Q4 2012, and down 4.54% on a QoQ basis from $20040.0 in Q3 2013.
Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue (2011 - 2013) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 3 years of Non-Current Deffered Revenue data on file, last reported at $19131.0 in Q4 2013.
- Quarterly Non-Current Deffered Revenue fell 12.56% year-over-year to $19131.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $19131.0 (down 12.56% YoY) and the FY2013 annual result came in at $19131.0, down 12.56% from the prior year.
- Non-Current Deffered Revenue eased to $19131.0 in Q4 2013, from $20040.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $22004.0 in Q2 2012 to a low of $9518.0 in Q4 2011.
- A 3-year average of $19212.7 and a median of $20653.0 in 2013 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2012 — Non-Current Deffered Revenue jumped 129.86% — and 2013, when it slipped 12.56%.
- Tracing CPRX's Non-Current Deffered Revenue over 3 years: stood at $9518.0 in 2011, then jumped by 129.86% to $21878.0 in 2012, then declined by 12.56% to $19131.0 in 2013.
- The last three Non-Current Deffered Revenue figures came in at $19131.0 (Q4 2013), $20040.0 (Q3 2013), and $20653.0 (Q2 2013), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 19,131.00 |
| Sep 30, 2013 | 20,040.00 |
| Jun 30, 2013 | 20,653.00 |
| Mar 31, 2013 | 21,265.00 |
| Dec 31, 2012 | 21,878.00 |
| Jun 30, 2012 | 22,004.00 |
| Dec 31, 2011 | 9,518.00 |